Chronic Oral Anticoagulation Therapy and Prognosis of Patients Admitted to Hospital for COVID‐19: Insights from the HOPE COVID‐19 Registry — José Miguel Rivera‐Caravaca (2022) | RDL Network
Hospitalized COVID-19 patients on prior OAC therapy had a higher risk of mortality and worse clinical outcomes compared to patients without prior OAC therapy, even after adjusting for comorbidities using a PSM. There were no differences in clinical outcomes in patients previously taking VKAs or DOACs. This trial is registered with NCT04334291/EUPAS34399.
Martino F. Pengo, Giulio Stefanini, Carlo Andrea Pivato, Davide Soranna, G Zambra, Antonella Zambon, Camilla Torlasco, Grzegorz Bilo, Gianluigi Condorelli, Gianfranco Parati
Utibe R. Essien, Karen Chiswell, Lisa A. Kaltenbach, Tracy Y Wang, Gregg C. Fonarow, Kevin L. Thomas, Mintu P. Turakhia, Emelia Benjamin, Fátima Rodríguez, Margaret C. Fang, Jared W. Magnani, Clyde W. Yancy, Jonathan P. Piccini
Darae Ko, Timothy Treu, Laura Tarko, Yuk‐Lam Ho, Sarah R. Preis, Ludovic Trinquart, David Gagnon, Kevin M. Monahan, Robert Helm, Ariela R. Orkaby, Steven A. Lubitz, Nicholas A. Bosch, Allan J. Walkey, Kelly Cho, Peter W.F. Wilson, Emelia Benjamin
Discussion(0)
No comments yet. Be the first to comment.